Zenas BioPharma (NASDAQ:ZBIO) Issues Earnings Results

Key Points

• Zenas BioPharma reported a quarterly loss of ($1.25) earnings per share, missing analysts' estimates of ($1.02) by ($0.23).
• The company's stock price rose to $15.64 during trading, with a market capitalization of $654.22 million and a PE ratio of -4.41.
• Analysts from HC Wainwright and Wedbush have issued a "buy" and "outperform" rating, with price targets set at $30.00 and $35.00, respectively.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($1.25) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.23), Zacks reports.

Zenas BioPharma Stock Performance

Shares of NASDAQ ZBIO traded up $0.73 during trading hours on Tuesday, hitting $15.64. The company's stock had a trading volume of 56,304 shares, compared to its average volume of 180,927. The stock has a 50-day moving average price of $12.21. The stock has a market capitalization of $654.22 million and a PE ratio of -4.41. Zenas BioPharma has a 12 month low of $5.83 and a 12 month high of $26.25.

Institutional Trading of Zenas BioPharma

An institutional investor recently raised its position in Zenas BioPharma stock. Geode Capital Management LLC raised its position in shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO - Free Report) by 4.6% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 373,617 shares of the company's stock after acquiring an additional 16,461 shares during the quarter. Geode Capital Management LLC owned approximately 0.89% of Zenas BioPharma worth $3,621,000 at the end of the most recent quarter.

Analyst Ratings Changes

A number of equities research analysts have weighed in on ZBIO shares. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Zenas BioPharma in a research report on Friday, May 16th. Wedbush restated an "outperform" rating and set a $35.00 price target on shares of Zenas BioPharma in a research report on Thursday, May 15th.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.